Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes
Efpeglenatide PK was well characterized across type 2 diabetes and obesity populations. Although some covariates affected PK parameters, their impact on exposure was not clinically meaningful. These results support a uniform dosing strategy without routine dose adjustment and provide quantitative evidence for stepwise dose escalation in ongoing clinical development for obesity.
Authors
- Jiyoung Seo (ORCID: https://orcid.org/0000-0002-0940-7654)
- H. G. Kim
- Soon Ho Choi (ORCID: https://orcid.org/0000-0002-2351-9775)
- Na Young Kim (ORCID: https://orcid.org/0000-0003-3685-2005)
- Hyeong-Seok Lim (ORCID: https://orcid.org/0000-0002-0352-6599)
- S.‐H. Park
Institutions
- Ulsan College (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- Hanmi Pharmaceutical (South Korea) (KR)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.3389/fphar.2025.1715585
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00